Last edition
News about "immunotherapy"
Junshi Biosciences expands toripalimab’s treatment footprint in China with regulatory approval for a new urothelial carcinoma indication, strengthening immunotherapy options for patients with advanced bladder cancer.
Immunotherapy | 25/05/2026 | By News Bureau
AstraZeneca's Imfinzi Combination Therapy Improves Survival Outcomes in Phase 3 Bladder Cancer Trial
AstraZeneca’s phase 3 VOLGA trial demonstrated significant survival benefits with Imfinzi and enfortumab vedotin in muscle-invasive bladder cancer patients who are ineligible for cisplatin-based chemotherapy, marking another positive milestone in the company’s immunotherapy programme.
Immunotherapy | 15/05/2026 | By News Bureau
Samsung Bioepis achieves positive Phase 1 results for Keytruda biosimilar candidate SB27
The biopharmaceutical company announced that its proposed pembrolizumab biosimilar, SB27, met primary pharmacokinetic endpoints in a global Phase 1 study involving non-small cell lung cancer patients, advancing its oncology biosimilar pipeline.
Immunotherapy | 08/05/2026 | By News Bureau | 144
Sobi Presents Positive Phase IIa Data for Gamifant in Interferon-Driven Sepsis
Sobi reports encouraging Phase IIa EMBRACE study results showing potential of Gamifant in interferon-gamma-driven sepsis, supporting precision medicine approaches in treating high-risk patients.
Immunotherapy | 19/03/2026 | By News Bureau | 107
A multi-institutional study published in the Journal for ImmunoTherapy of Cancer finds that an AI-based imaging biomarker can predict immunotherapy outcomes and detect early treatment response in lung cancer patients.
Immunotherapy | 11/03/2026 | By News Bureau | 114
Jiahui International Cancer Centre in Shanghai treats a US patient with advanced Non?Small Cell Lung Cancer using Ivonescimab, an experimental immunotherapy currently available only in China.
Immunotherapy | 09/03/2026 | By News Bureau
The FDA has granted Priority Review to Datroway for first-line treatment of metastatic triple-negative breast cancer patients ineligible for immunotherapy, with a regulatory decision expected in Q2 2026.
Immunotherapy | 04/02/2026 | By News Bureau | 169
Immorta Bio Reports Tumour Reduction Across Multiple Cancer Models with SenoVax
Immorta Bio has reported promising pre-clinical results showing that its anti-aging vaccine, SenoVax, reduced tumours across multiple validated cancer models. Developed in collaboration with academic institutions, the platform aims to dismantle tumour defense mechanisms and offer a non-toxic, longevity-driven approach to cancer treatment.
Immunotherapy | 05/12/2025 | By Dineshwori | 591
Greenwich LifeSciences Expands Flamingo-01 Breast Cancer Trial to Ireland
Greenwich LifeSciences has expanded its Phase III clinical trial, FLAMINGO-01, evaluating GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences, to Ireland.
Immunotherapy | 18/09/2025 | By Dineshwori | 172
Cantargia Secures US Patent for Nadunolimab in Cancer Combination Therapies
Cantargia has announced that the United States Patent and Trademark Office (USPTO) has granted a new patent covering its antibody, nadunolimab.
Immunotherapy | 27/08/2025 | By Dineshwori | 279
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy